Finance

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

Published by Global Banking & Finance Review

Posted on October 6, 2025

1 min read

· Last updated: January 21, 2026

Add as preferred source on Google
AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives

AstraZeneca Secures $555 Million Deal for Gene-Editing Technology

AstraZeneca's Strategic Partnership with Algen

(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.

Details of the Agreement

The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said.

Implications for Gene-Editing Therapies

Reuters could not immediately confirm the FT report.

(Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)

Key Takeaways

  • AstraZeneca signs a $555 million deal with Algen Biotechnologies.
  • The deal focuses on Crispr gene-editing technology.
  • AstraZeneca gains exclusive rights for therapy development.
  • The partnership aims to commercialize new therapies.
  • Reuters has not confirmed the Financial Times report.

Frequently Asked Questions

What is gene-editing technology?
Gene-editing technology refers to techniques that allow scientists to modify an organism's DNA. This can lead to advancements in medicine, agriculture, and biotechnology by enabling precise changes to genetic material.
What is Crispr technology?
Crispr technology is a revolutionary gene-editing tool that enables precise modifications to DNA. It allows for targeted changes in the genetic code, which can lead to advancements in genetic research and therapy.
What is commercialization in biotechnology?
Commercialization in biotechnology refers to the process of bringing biotechnological innovations and products to market. This includes development, marketing, and sales of biotech products to generate profit.
What is the significance of a $555 million deal?
A $555 million deal signifies a substantial investment and commitment to a partnership or project. In the context of biotechnology, it reflects confidence in the potential of the technology involved.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category